title: Effects of UFT on thymidylate synthase and dihydropyrimidine dehydrogenase activities in lung cancer.
abstract: BACKGROUND
  We measured thymidylate synthase (TS) activity, dihydropyrimidine dehydrogenase (DPD) activity and TS inhibition rate (TSIR) in tumor tissue and lymph node metastasis, considered predictors of response to DIFs, in patients with lung cancer.
  
  
  METHODS
  Fourteen patients with non-small cell lung cancer (NSCLC) were given UFT for 1-2 weeks before surgery. Total TS activity (total TS), TSIR and DPD activity were measured in tumors, lymph node metastases and normal lung and lymph nodes.
  
  
  RESULTS
  Total TS activity and DPD activity were significantly higher in lung tumors than in normal lung (TS, p = 0.0225; DPD, p < 0.0001). Total TS activity was slightly but not significantly higher in lymph node metastases than in normal lymph nodes. DPD activity and TSIR were similar in the other tissues.
  
  
  CONCLUSIONS
  After preoperative treatment with UFT, TS and DPD activities are significantly higher in lung tumor tissue than in normal lung tissue in patients with NSCLC.
authors.affiliation: Department of General Thoracic Surgery, Juntendo University, School of Medicine, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. miyagen@med.juntendo.ac.jp
authors.forename: Hideaki
authors.initials: H
authors.lastname: Miyamoto
authors.forename: Atsuo
authors.initials: A
authors.lastname: Morio
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Izumi
authors.forename: Akio
authors.initials: A
authors.lastname: Yamazaki
authors.forename: Zumin
authors.initials: Z
authors.lastname: Wang
authors.forename: Toshiroh
authors.initials: T
authors.lastname: Futagawa
authors.forename: Satoshi
authors.initials: S
authors.lastname: Sonobe
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology* / Q000601:surgery; D003131:Combined Modality Therapy; D042943:Dihydrouracil Dehydrogenase (NADP) / Q000378:metabolism*; D005472:Fluorouracil / Q000097:blood / Q000493:pharmacokinetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000601:surgery; D008207:Lymphatic Metastasis; D005641:Tegafur / Q000008:administration & dosage; D013940:Thymidylate Synthase / Q000378:metabolism*; D014498:Uracil / Q000008:administration & dosage
chemical_list: D005641:Tegafur; D014498:Uracil; D042943:Dihydrouracil Dehydrogenase (NADP); D013940:Thymidylate Synthase; D005472:Fluorouracil